Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in First Relapse of Childhood B-ALL
NCT02101853Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by National Cancer Institute. Started Dec 2014; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02101853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101853.